New results from AlzeCure’s pain project TrkA-NAM presented at the IASP pain conference

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s presentation and poster on its preclinical project TrkA-NAM for osteoarthritic pain and other severe pain disorders, which were presented at the IASP 2021 World Congress on Pain June 9-11 and 16-18, are now available in full on the company’s website.

The poster presentation, given by Dr. Pontus Forsell, Head of Discovery at AlzeCure and project leader of the TrkA-NAM project, concludes that the NGF/TrkA pathway is a well validated and a promising alternative for new analgesics without the side effects and dependency issues observed with opioids. Identification of selective and potent TrkA-NAM’s could potentially avoid some of the side effects observed for anti-NGF antibodies due to a more selective mechanism of action, while retaining the analgesic efficacy. The lead optimization program has identified very potent and selective TrkA-NAM’s and demonstrated pain relief in preclinical models in vivo, both in neuropathic pain and arthritis suggesting a broad indication potential.
“The data presented in the poster presentation is very promising and a clear validation of our R&D platform. Our work to select a drug candidate for this highly interesting project continues, and we expect to announce a candidate before the end of 2021,” said Martin Jönsson, CEO of AlzeCure Pharma AB.
The authors for the late-breaking abstract, titled Negative Allosteric Modulators of TrkA for the Treatment of Pain include Dr. Pontus Forsell, Head of Discovery at AlzeCure, Dr. Gunnar Nordvall, Head of Chemistry at AlzeCure, Dr. Magnus Halldin, Head of DMPK & Safety Assessment at AlzeCure, and Dr. Johan Sandin, CSO at AlzeCure.
The poster and recorded presentation are available on AlzeCure’s website: